- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05461768
A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors
A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of BL-M07D1injection in Patients With Locally Advanced or Metastatic HER2-positive/Low-expression Breast Cancer and Other Solid Tumors
In phase Ia study, the safety and tolerability of BL-B07D1 in patients with locally advanced or metastatic HER2-positive/low-expression breast cancer and other solid tumors will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of BL-M07D1.
In phase Ib study, the safety and tolerability of BL-M07D1 at the phase Ia recommended dose will be further investigated, and recommended phase II dose (RP2D) for phase II clinical studies will be determined.
In addition, the preliminary efficacy, pharmacokinetic characteristics, and immunogenicity of BL-M07D1 in patients
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Hai Zhu, PHD
- Phone Number: +8613980051002
- Email: zhuhai@baili-pharm.com
Study Contact Backup
- Name: Sa Xiao, PHD
- Phone Number: +8615013238943
- Email: xiaosa@baili-pharm.com
Study Locations
-
-
Fujian
-
Fuzhou, Fujian, China
- Recruiting
- Fujian cancer hospital
-
Contact:
- Rongbo Lin
-
-
Guangdong
-
Dongguan, Guangdong, China
- Recruiting
- Dongguan People's Hospital
-
Contact:
- Jun Jia
-
Principal Investigator:
- Jun Jia
-
Principal Investigator:
- Ling Guan
-
-
Guangzhou
-
Guangdong, Guangzhou, China, 510120
- Recruiting
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University
-
Contact:
- Erwei Song
- Phone Number: +8613926477694
- Email: songew@mail.sysu.edu.cn
-
Principal Investigator:
- Erwei Song, PHD
-
Principal Investigator:
- Herui Yao, PHD
-
-
Henan
-
Zhengzhou, Henan, China
- Recruiting
- The First Affiliated Hospital of Zhengzhou University
-
Contact:
- Hong Zong
-
-
Hubei
-
Wuhan, Hubei, China
- Recruiting
- Zhongnan Hospital of Wuhan University
-
Contact:
- Yahua Zhong
-
Principal Investigator:
- Yahua Zhong
-
Principal Investigator:
- Jianying Huang
-
-
Shandong
-
Jinan, Shandong, China
- Recruiting
- Jinan Central Hospital
-
Contact:
- Meili Sun
-
Principal Investigator:
- Qing Wen
-
Principal Investigator:
- Meili Sun
-
-
Zhejiang
-
Hangzhou, Zhejiang, China
- Recruiting
- Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine
-
Contact:
- Xian Wang
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- 1. Sign the informed consent voluntarily and follow the program requirements
- 2. No gender limitation;
- 3. Age: ≥18 years old and ≤75 years old (Stage Ia);≥18 years old (Ib);
- 4. Expected survival time ≥3 months;
- 5. Inoperable locally advanced or metastatic HER2-positive/low-expression breast cancer and other solid tumors that have been histopathologically and/or cytologically confirmed and have failed standard therapy, or are not available for standard therapy, or are not currently eligible for standard therapy; HER2 positive: IHC3+, or IHC2+ and ISH positive; HER2 low expression: IHC2+ and ISH negative, or IHC1+;
- 6. Agree to provide archived tumor tissue samples or fresh tissue samples from the primary tumor or metastatic tumor within 2 years (to detect the expression of HER2 protein in tumor pathological tissue and explore the correlation between HER2 protein and bl-M07D1 validity index); If subjects are unable to provide tumor tissue samples, they will be admitted after evaluation by the investigator if other admission criteria are met.
- 7. Must have at least one measurable lesion as defined by RECIST V1.1;
- 8. ECOG score of 0 or 1;
- 9. Toxicity of previous antitumor therapy has returned to level ≤1 as defined by NCI-CTCAE V5.0 (the investigator considered asymptomatic laboratory abnormalities, such as elevated ALP, hyperuricemia, and elevated blood glucose, etc.); Except for toxicity that the investigator judged to have no safety risk, such as alopecia, pigmentation, grade 2 peripheral neurotoxicity, etc.);
- 10. No serious cardiac dysfunction, left ventricular ejection fraction ≥50%;
- 11. Organ function level must meet the following requirements and meet the following standards: A) Bone marrow function: absolute neutrophil count (ANC) ≥1.5×10^9/L, platelet count ≥90×10^9/L, hemoglobin ≥90 g/L; B) Liver function: total bilirubin (TBIL≤1.5 ULN), AST and ALT ≤2.5 ULN in patients without liver metastasis, AST and ALT ≤5.0 ULN in patients with liver metastasis; C) Renal function: creatinine (Cr) ≤1.5 ULN, or creatinine clearance (Ccr) ≥50 mL/min (according to the Cockcroft and Gault formula).
- 12. Coagulation function: International standardized ratio (INR) ≤1.5, and activated partial thrombin time (APTT) ≤1.5ULN;
- 13. Urinary protein ≤2+ or ≤1000mg/24h;
- 14. For premenopausal women at risk of fertility, pregnancy tests must be performed within 7 days prior to the start of treatment. Serum/urine pregnancy must be negative and must be non-lactation; All enrolled patients (male and female) should use adequate barrier contraception throughout the treatment cycle and 6 months after the end of treatment
Exclusion Criteria:
- 1. Prior use of chemotherapy, biotherapy, immunotherapy, radical radiotherapy, major surgery (as defined by the investigator), targeted therapy (including small molecule tyrosine kinase inhibitors) and other antitumor therapies within 4 weeks or 5 half-lives (whichever is less) prior to initial dosing; Mitomycin and nitrosourea were administered within 6 weeks prior to initial administration; For oral fluorouracil drugs such as gio, capecitabine, or palliative radiotherapy within 2 weeks before initial administration; The Chinese medicine with anti-tumor indication was given within 2 weeks before the first administration.
- 2. Prior ADC treatment (phase Ib only) with the toxin of camptothecin derivatives (topoisomerase I inhibitors);
- 3. History of severe heart disease, such as symptomatic congestive heart failure (CHF) grade 2 or greater (CTCAE 5.0), NYHA grade 2 or greater heart failure, history of transmural myocardial infarction, unstable angina, etc.;
- 4. QT prolongation (male QTc > 450 msec or female QTc > 470 msec), complete left bundle branch block, III atrioventricular block;
- 5. Active autoimmune diseases and inflammatory diseases, such as: systemic lupus erythematosus, systemic treatment of psoriasis, rheumatoid arthritis, inflammatory bowel disease, and hashimoto's thyroiditis, etc., with the exception of type I diabetes, only replacement therapy can control the hypothyroidism, no systemic treatment of skin disease (e.g., vitiligo, psoriasis);
- 6. Other malignancies diagnosed within 5 years prior to first administration, except for radical basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or radical resected carcinoma in situ;
- 7. Screening for unstable thrombotic events such as deep vein thrombosis, arterial thrombosis and pulmonary embolism requiring therapeutic intervention within the first 6 months; Infusion device-related thrombosis is excluded;
- 8. Patients with poorly controlled pleural effusion with clinical symptoms were judged by researchers to be unsuitable for inclusion;
- 9. Hypertension poorly controlled by medications (systolic & GT; 150 mmHg or diastolic pressure & GT; 100 mmHg);
- 10. According to CTCAE V5.0, patients were defined as ≥3 grade of lung disease, ≥2 grade of radioactive lung disease, existing or with a history of ILD;
- 11. Symptoms of active CNS metastasis. But the researchers concluded that patients with stable parenchymal metastases could be included. The definition of stability must meet the following four requirements: A. Seizureless state lasting > 12 weeks with or without antiepileptic drugs; B. Glucocorticoids are not required; C. Two consecutive MRI scans (at least 4 weeks between scans) showed stable imaging state; D. Asymptomatic patients have been stable for more than 1 month after treatment;
- 12. Patients with a history of allergy to recombinant humanized antibody or human-mouse chimeric antibody or to any excipient component of BL-M07D1;
- 13. Prior organ transplantation or allogeneic hematopoietic stem cell transplantation (ALLO-HSCT);
- 14. Equivalent cumulative dose of doxorubicin in anthracycline adjuvant therapy was > 360 mg/m^2;
- 15. Positive human immunodeficiency virus antibody (HIVAb), active tuberculosis, active hepatitis B virus infection (HBV-DNA copy number > lower limit) or active hepatitis C virus infection (HCV antibody positive and HCV-RNA > lower limit);
- 16. Active infections requiring systemic treatment, such as severe pneumonia, bacteremia, sepsis, etc.
- 17. Participated in another clinical trial within 4 weeks prior to initial administration (starting from the time of last administration);
- 18. Pregnant or nursing women;
- 19. Other conditions considered inappropriate for participation in this clinical trial by the investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Study treatment
Participants receive BL-M07D1 as intravenous infusion for the first cycle (3 weeks).
Participants with clinical benefit could receive additional treatment for more cycles.
The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons.
|
Administration by intravenous infusion
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Phase Ia: Dose limiting toxicity (DLT)
Time Frame: Up to 21 days after the first dose
|
The DLT observation period was the first treatment period for each dose level, and the DLT observation period was extended if there was a delay in administration .
|
Up to 21 days after the first dose
|
Phase Ia: Maximum tolerated dose (MTD)
Time Frame: Up to 21 days after the first dose
|
In the dose escalation stage, MTD was selected as the highest dose whose DLT rate estimate was closest to the target DLT rate, but did not exceed the upper bound of the EQUIVALENT interval of DLT rate.
|
Up to 21 days after the first dose
|
Phase Ib: Phase II clinical study recommended dose (RP2D)
Time Frame: Up to 21 days after the first dose
|
The RP2D is defined as the dose level chosen by the sponsor (in consultation with the investigators) for phase II study, based on safety, tolerability, efficacy, PK, and PD data collected during the dose escalation study of BL-M07D1
|
Up to 21 days after the first dose
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective Response Rate (ORR)
Time Frame: Up to approximately 24 months
|
ORR is defined as the percentage of participants, who has a CR (disappearance of all target lesions) or PR (at least a 30% decrease in the sum of diameters of target lesions).
The percentage of participants who experiences a confirmed CR or PR is according to RECIST 1.1.
|
Up to approximately 24 months
|
Disease Control Rate (DCR)
Time Frame: Up to approximately 24 months
|
The DCR is defined as the percentage of participants who has a CR, PR, or Stable Disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease [PD: at least a 20% increase in the sum of diameters of target lesions and an absolute increase of at least 5 mm.
The appearance of one or more new lesions is also considered PD]).
|
Up to approximately 24 months
|
Treatment-Emergent Adverse Event (TEAE)
Time Frame: Up to approximately 24 months
|
TEAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally emerging, or any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition during the treatment of BL-B07D1 .
The type, frequency and severity of TEAE will be evaluated during the treatment of BL-M07D1 .
|
Up to approximately 24 months
|
ADA (anti-drug antibody)
Time Frame: Up to approximately 24 months
|
Incidence and titer of ADA of BL-M07D1 will be evaluated.
|
Up to approximately 24 months
|
Nab (neutralizing antibody)
Time Frame: Up to approximately 24 months
|
Incidence and titer of Nab of BL-M07D1 will be evaluated
|
Up to approximately 24 months
|
Duration of Response (DOR) Duration of Response (DOR) Duration of Response (DOR) Duration of Response (DOR) Duration of Response (DOR) Duration of Response (DOR)
Time Frame: Up to approximately 24 months
|
The DOR for a responder is defined as the time from the participant's initial objective response to the first date of either disease progression or death, whichever occurs first.
|
Up to approximately 24 months
|
Progression-free Survival (PFS)
Time Frame: Up to approximately 24 months
|
The PFS is defined as the time from the participant's first dose of BL-B07D1 to the first date of either disease progression or death, whichever occurs first.
|
Up to approximately 24 months
|
T1/2
Time Frame: Up to 21 days after the first dose
|
Half-life (T1/2) of BL-M07D1 will be investigated.
|
Up to 21 days after the first dose
|
Ctrough
Time Frame: Up to 21 days after the first dose
|
Ctough is defined as the lowest serum concentration of BL-M07D1 prior to the next dose will be administered.
|
Up to 21 days after the first dose
|
Cmax
Time Frame: Up to 21 days after the first dose
|
Maximum serum concentration (Cmax) of BL-M07D1 will be investigated
|
Up to 21 days after the first dose
|
AUC0-t
Time Frame: Up to 21 days after the first dose
|
AUC0-t is defined as area under the serum concentration-time curve from time 0 to the time of the last measurable concentration
|
Up to 21 days after the first dose
|
Tmax
Time Frame: Up to 21 days after the first dose
|
Time to maximum serum concentration (Tmax) of BL-M07D1 will be investigated
|
Up to 21 days after the first dose
|
CL (Clearance)
Time Frame: Up to 21 days after the first dose
|
CL in the serum of BL-M07D1 per unit of time will be investigated.
|
Up to 21 days after the first dose
|
Collaborators and Investigators
Investigators
- Principal Investigator: Erwei Song, PHD, Sun Yat-sen Memorial Hospital,Sun Yat-sen University
- Principal Investigator: Herui Yao, PHD, Sun Yat-sen Memorial Hospital,Sun Yat-sen University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- BL-M07D1-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)WithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer
Clinical Trials on BL-M07D1
-
SystImmune Inc.RecruitingCervical Cancer | Ovarian Cancer | Endometrial Cancer | Urothelial Carcinoma | Biliary Tract CancerUnited States
-
Sichuan Baili Pharmaceutical Co., Ltd.Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.RecruitingGynecological MalignanciesChina
-
Sichuan Baili Pharmaceutical Co., Ltd.Not yet recruitingNon-small Cell Lung CancerChina
-
Sichuan Baili Pharmaceutical Co., Ltd.RecruitingHer2-positive/Low-expression Urinary and Digestive Tract TumorsChina
-
Sichuan Baili Pharmaceutical Co., Ltd.SystImmune Inc.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.RecruitingOther Solid Tumors | Locally Advanced or Metastatic Digestive Tract TumorsChina
-
Sichuan Baili Pharmaceutical Co., Ltd.Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.Not yet recruitingHER2-positive Breast CancerChina
-
Sichuan Baili Pharmaceutical Co., Ltd.RecruitingRelapsed/Refractory Acute Myeloid Leukemia (R/R AML)China
-
Sichuan Baili Pharmaceutical Co., Ltd.Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.RecruitingSolid Tumor | Gynecological Malignant TumorChina
-
Sichuan Baili Pharmaceutical Co., Ltd.SystImmune Inc.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.RecruitingSolid Tumor | Locally Advanced or Metastatic Digestive Tract TumorsChina
-
Sichuan Baili Pharmaceutical Co., Ltd.SystImmune Inc.; Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.Recruiting